Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	FLT3 exon 14 ins FLT3 D835H
Gene Variant Detail	FLT3 D835H (gain of function) FLT3 exon 14 ins (gain of function - predicted)
Relevant Treatment Approaches

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 17 of 17 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 exon 14 ins FLT3 D835H	leukemia	resistant		Pexidartinib	Clinical Study	Actionable	In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 D835H mutation on the same allele as the FLT3-ITD mutation (PMID: 25847190).	25847190
FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	sensitive		FF-10101	Preclinical - Pdx	Actionable	In a preclinical study, FF-10101 inhibited cell growth in AML-patient-derived xenograft models with FLT3-ITD/D835H compound mutations (PMID: 29187377).	29187377
FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	resistant		Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FLT3 D835H was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Nexavar (sorafenib) (PMID: 35344039).	35344039
FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	resistant		Crenolanib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FLT3 D835H was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on Crenolanib (CP-868596) (PMID: 35344039).	35344039
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	sensitive		Dubermatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dubermatinib (TP-0903) inhibited growth of transformed cells expressing a FLT3-ITD mutation and FLT3 D835H in culture (PMID: 33268594).	33268594
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	sensitive		FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101 treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835H in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	sensitive		FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, FF-10101 treatment inhibited growth of acute myeloid leukemia cells harboring FLT3-ITD and FLT3 D835H in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 ITD with FLT3 D835H in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835H in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in acute myeloid leukemia cells harboring FLT3 ITD with FLT3 D835H in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	resistant		Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring FLT3 ITD with FLT3 D835H were resistant to Vanflyta (quizartinib) in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	sensitive		Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, Crenolanib (CP-868596) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835H in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	predicted - resistant		Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 D835H were moderately resistant to treatment with Vanflyta (quizartinib) in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	sensitive		Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835H in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 D835H	hematologic cancer	sensitive		Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vonjo (pacritinib) inhibited viability in a transformed cell line expressing a FLT3-ITD mutation and FLT3 D835H in culture (PMID: 31102119).	31102119
FLT3 exon 14 ins FLT3 D835H	acute myeloid leukemia	sensitive		RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 inhibited viability in an acute myeloid leukemia cell line harboring FLT3 ITD and expressing FLT3 D835H in culture (PMID: 37992684).	37992684
FLT3 exon 14 ins FLT3 D835H	Advanced Solid Tumor	resistant		Pexidartinib	Preclinical	Actionable	In a preclinical study, FLT3 D835H conferred resistance to PLX3397 in transformed cells when expressed as a compound mutation with FLT3-ITD in culture (PMID: 25847190).	25847190

Showing 1 to 17 of 17 entries

Filter rows: